NEWS
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
KORU Medical Systems (NASDAQ: KRMD) announced a collaboration with a global pharmaceutical company to initiate a feasibility study for their Freedom Infusion System. This system, designed for subcutaneous administration, will be tested with an FDA and EMA approved oncology biologic drug currently administered manually by healthcare professionals. The Freedom System, a mechanical ambulatory drug delivery device, can deliver large volumes of medications from 2mL to over 100mL. If successful, the study could lead to the commercialization of the system within 12 months, addressing a growing trend in oncology for subcutaneous drug administration.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2879Followers
108Following
30KVisitors
Follow